Torren Management’s Moderna MRNA Stock Holding History

Torren Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16	Closed	-$472	–	1266
2025 Q4	$472	Buy	+16	New	+$435	﹤0.01%	1346

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Torren Management's MRNA Position: Q1 2026 in Review

Torren Management sold out of Moderna (MRNA) in Q1 2026, closing a stake of 16 shares — an estimated $472 sold.

Torren Management first reported a position in MRNA in Q4 2025 and held it in 1 quarter. The position peaked at $472 in Q4 2025. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Torren Management reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Torren Management sold 16 Moderna shares in Q1 2026, an estimated $472.
Torren Management first reported a position in Moderna in Q4 2025 and held it in 1 quarter.
Torren Management's Moderna position peaked at $472 in Q4 2025.
723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.